Wednesday, July 8, 2026

biotech · Oculopharyngeal Muscular Dystrophy · Head and Neck Squamous Cell Carcinoma · BNTC

Benitec Biopharma

Benitec Biopharma clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Hayward, USA HQ
2001 Founded
27 Employees
Public company Type
BNTC · NYSE Ticker
Company details
Status
Public
HQ
Hayward, USA
Founded
2001
Employees
27
Programs
2
Drugs
3
Patents
13
Intelligence · Clinical Programs

Benitec Biopharma projects

2 ClinicalTrials.gov programs sponsored by Benitec Biopharma.

Benitec Biopharma has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. BB-301: Dose escalation phase 1b cohort 1

    Benitec Biopharma

    Oculopharyngeal Muscular Dystrophy

    phase 2 gene therapy active

    1 trial
  2. BB-401

    Benitec Biopharma

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Benitec Biopharma have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.